Abbott Vascular On Track For 60% Growth In 2007
This article was originally published in The Gray Sheet
Executive Summary
Abbott's vascular business is on target to achieve growth of "at least 60%" this year following a strong first quarter that saw continued success of the firm's Xience V everolimus-eluting coronary stent outside of the United States, the company says
You may also be interested in...
Abbott’s SPIRITs Are Raised By Positive Drug-Eluting Stent Data At ACC
Abbott's SPIRIT III trial for its Xience V everolimus-eluting stent bodes well for the device's market potential and points to a new direction for stent manufacturers' premarket relationship with FDA
Abbott Sells IVD, Point-Of-Care Diagnostics To GE For $8.13 Bil.
With GE's $8.13 billion cash purchase of Abbott Laboratories' core in vitro diagnostics unit Jan. 18, the corporate giant is betting it can accelerate growth in a business still recovering from protracted regulatory challenges in the U.S
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.